

Establishing a Clinical Trial Basis Through Nonclinical Evaluation of CR-C003, a First-in-Class Drug Candidate for the Treatment of Inflammatory Bowel Disease

IMMUNOLOGY	Preclinical
Product Type	Small molecule
Indication	Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC) and Crohn's Disease (CD)
Target	CR-E1 (undisclosed)
MoA(Mechanism of Action)	CR-C003 inhibits K63-linked polyubiquitination of CR-E1, thereby blocking its auto-ubiquitination and stabilization. This suppression leads to inhibition of NF-κB signaling and Th17-mediated chronic inflammatory responses.
Competitiveness	<ul style="list-style-type: none"> • First-in-class small-molecule inhibitor targeting CR-E1 • Demonstrated strong efficacy in multiple IBD murine models (DSS-induced model, PAC-induced model in IL-10 KO mice, T-cell adoptive transfer model) • Superior therapeutic outcome compared to TL1A inhibitors and JAK inhibitors • Wide safety margin and excellent oral bioavailability suitable for chronic treatment
Development Stage	Preclinical
Route of Administration	Oral

Any unauthorized distribution or reproduction of this material is strictly prohibited.